Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 6:30 pm Sale | 2024-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | RA Capital Management, L.P. | 4,564,867 9.900% | -533,344 (-10.46%) | Filing History |
| 2025-02-14 6:09 pm Sale | 2024-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | Venrock Healthcare Capital Partners III, L.P. | 2,952,371 6.400% | -1,447,629 (-32.90%) | Filing History |
| 2025-02-14 4:20 pm Sale | 2024-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | BIOTECHNOLOGY VALUE FUND L P | 4,834,297 9.990% | -2,548,345 (-34.52%) | Filing History |
| 2025-02-14 11:34 am Sale | 2024-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | JANUS HENDERSON GROUP PLC JHG | 2,252,240 4.900% | -884,847 (-28.21%) | Filing History |
| 2025-02-14 08:40 am Sale | 2024-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | Deep Track Capital LP | 609,900 1.320% | -3,486,552 (-85.11%) | Filing History |
| 2025-02-10 5:28 pm Purchase | 2024-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | GOLDMAN SACHS GROUP INC GS | 4,423,435 9.600% | 831,575 (+23.15%) | Filing History |
| 2024-12-06 4:28 pm Purchase | 2024-11-30 | 13G | 4D Molecular Therapeutics, Inc. FDMT | BlackRock Inc. BLK | 4,965,019 10.700% | 96,230 (+1.98%) | Filing History |
| 2024-11-15 5:05 pm Sale | 2024-11-13 | 13G | 4D Molecular Therapeutics, Inc. FDMT | RA Capital Management, L.P. | 5,098,211 11.000% | -103,934 (-2.00%) | Filing History |
| 2024-11-14 5:46 pm Purchase | 2024-09-30 | 13G | 4D Molecular Therapeutics, Inc. FDMT | RA Capital Management, L.P. | 5,202,145 9.990% | 1,038,934 (+24.96%) | Filing History |
| 2024-11-14 4:31 pm Sale | 2024-09-30 | 13G | 4D Molecular Therapeutics, Inc. FDMT | VIKING GLOBAL INVESTORS LP | 0 0.000% | -4,247,914 (Position Closed) | Filing History |
| 2024-11-14 3:15 pm Purchase | 2024-09-30 | 13G | 4D Molecular Therapeutics, Inc. FDMT | JANUS HENDERSON GROUP PLC JHG | 3,137,087 6.000% | 43,791 (+1.42%) | Filing History |
| 2024-11-14 09:13 am Purchase | 2024-09-30 | 13G | 4D Molecular Therapeutics, Inc. FDMT | Deep Track Capital LP | 4,096,452 7.880% | 1,812,080 (+79.33%) | Filing History |
| 2024-11-13 4:08 pm Purchase | 2024-09-30 | 13G | 4D Molecular Therapeutics, Inc. FDMT | BIOTECHNOLOGY VALUE FUND L P | 7,382,642 14.200% | 3,375,229 (+84.22%) | Filing History |
| 2024-11-12 12:12 pm Unchanged | 2024-09-30 | 13G | 4D Molecular Therapeutics, Inc. FDMT | VANGUARD GROUP INC | 2,767,717 5.320% | 0 (Unchanged) | Filing History |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | 4D Molecular Therapeutics, Inc. FDMT | BlackRock Inc. BLK | 4,868,789 9.400% | 0 (Unchanged) | Filing History |
| 2024-11-06 6:07 pm Purchase | 2024-09-30 | 13G | 4D Molecular Therapeutics, Inc. FDMT | GOLDMAN SACHS GROUP INC GS | 3,591,860 6.900% | 3,591,860 (New Position) | Filing History |
| 2024-11-04 10:55 am Purchase | 2024-09-30 | 13G | 4D Molecular Therapeutics, Inc. FDMT | VANGUARD GROUP INC | 2,767,717 5.320% | 2,767,717 (New Position) | Filing History |
| 2024-10-21 4:11 pm Purchase | 2024-09-30 | 13G | 4D Molecular Therapeutics, Inc. FDMT | BlackRock Inc. BLK | 4,868,789 9.400% | 1,404,202 (+40.53%) | Filing History |
| 2024-02-14 8:51 pm Purchase | 2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | Venrock Healthcare Capital Partners III, L.P. | 4,400,000 8.900% | 1,512,483 (+52.38%) | Filing History |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | RA Capital Management, L.P. | 4,163,211 9.700% | 1,373,490 (+49.23%) | Filing History |